Common Contracts
4 similar Assignment contracts by Theravance Biopharma, Inc.
CONSENT TO ASSIGNMENTAssignment • August 14th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Consent to Assignment (this “Consent”) is made as of May 21, 2014, by ARE-901/951 GATEWAY BOULEVARD, LLC, a Delaware limited liability company, having an address of 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), to THERAVANCE, INC., a Delaware corporation (“Tenant”), and THERAVANCE BIOPHARMA US, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.
CONSENT TO ASSIGNMENTAssignment • August 14th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Consent to Assignment (this “Consent”) is made as of May 21, 2014, by ARE-901/951 GATEWAY BOULEVARD, LLC, a Delaware limited liability company, having an address of 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), to THERAVANCE, INC., a Delaware corporation (“Tenant”), and THERAVANCE BIOPHARMA US, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.
CONSENT TO ASSIGNMENTAssignment • April 30th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Consent to Assignment (this “Consent”) is made as of , 201 , by ARE-901/951 GATEWAY BOULEVARD, LLC, a Delaware limited liability company, having an address of 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), to THERAVANCE, INC., a Delaware corporation (“Tenant”), and THERAVANCE BIOPHARMA US, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.
CONSENT TO ASSIGNMENTAssignment • April 30th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Consent to Assignment (this “Consent”) is made as of , 201 , by ARE-901/951 GATEWAY BOULEVARD, LLC, a Delaware limited liability company, having an address of 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), to THERAVANCE, INC., a Delaware corporation (“Tenant”), and THERAVANCE BIOPHARMA US, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.
